Intensity Therapeutics Wins 2026 Pinnacle Award for INT230-6 Cancer Therapy April 16, 2026 by Mathieu Maurice Intensity Therapeutics, Inc., a late-stage biotechnology firm, focuses on discovering and developing proprietary cancer treatments using its non-covalent drug-conjugation technology. This approach is designed to destroy tumors while enhancing the …